Neurofilament light emerges as key biomarker for monitoring neuronal health and drug discovery

Neurofilament light (NfL) is emerging as a key biomarker for monitoring neuronal health and disease progression in central nervous system (CNS) research. Recent advancements highlight its role in drug discovery, treatment monitoring, and neurotoxicity detection. NfL levels can indicate axonal health and disease progression across various research stages, from laboratory studies to clinical trials. Elevated NfL levels in cerebrospinal fluid and plasma correlate with neurodegenerative diseases, aiding in diagnosis and treatment response evaluation. Artificial intelligence is enhancing biomarker selection by analyzing large datasets to identify new targets. Collaborations, like that between Charles River Laboratories and Aitia, aim to improve the efficiency of biomarker discovery in drug development.